感染COVID-19与献血者血浆纤维连接蛋白和凝血功能的关系研究

Study on the relationship between COVID-19 infection and plasma fibronectin and coagulation function in blood donors

目的:探讨感染新型冠状病毒疾病(COVID-19)与献血者的血浆纤维连接蛋白(pFN)和凝血功能的关系。方法:选取2022年12月1日—2023年1月31日在血液中心捐献血液的献血者82例为研究对象,根据是否感染COVID-19及感染康复分为未感染组(35例)和感染康复组(47例)。留取标本检测pFN、血常规、凝血因子Ⅷ(FⅧ)、凝血功能[凝血酶原时间(PT)、凝血酶时间(TT)、活化部分凝血酶时间(APTT)、纤维蛋白原(Fib)及D-二聚体(D-Dimer,D-D)]。采用独立样本t检验,比较2组pFN和凝血功能的变化。结果:未感染组及感染康复组的pFN分别为(282.90±156.00)mg/L和(197.80±96.95)mg/L,2组比较差异有统计学意义(P<0.05)。2组的血小板计数、PT、TT、APTT、Fib、D-D值均在正常范围内,差异无统计学意义(P>0.05)。结论:轻症感染COVID-19康复患者pFN消耗增加,主要参与机体免疫炎症反应,对凝血功能的影响较小,血液符合《全血及成分血质量要求(GB 18469—2012)》的标准。

Objective To investigate the relationship between plasma fibronectin(pFN)and coagulation function in blood donors infected with COVID-19.Methods A total of 82 blood donors who donated blood at the blood center from December 1,2022 to January 31,2023 were selected as the study subjects.They were divided into two groups:the non-infected group(35 cases)and the infected-recovered group(47 cases)according to whether they were infected with COVID-19 and whether they had recovered.Samples were collected to test pFN,blood routine,coagulation factorⅧ(FⅧ)and coagulation function which included prothrombin time(PT),thrombin time(TT),activated partial thromboplastin time(APTT),fibrinogen(Fib),and D-Dimer(D-D).The independent sample t-test was used to compare the changes in pFN and coagulation function between the two groups.Results The pFN of the non-infected group and the infected-recovered group were(282.9±156.00)mg/L and(197.80±96.95)mg/L,respectively.There was a significant difference between the two groups(P<0.05).The platelet count,PT,TT,APTT,Fib and D-D values of both groups were within the normal range,and the difference was not statistically significant(P>0.05).Conclusion For mild COVID-19 patients who had recovered,pFN consumption may increase,mainly participating in the body's immune inflammatory response,with little effect on coagulation function,whose blood can meet the standard of Quality Requirements for Whole Blood and Blood Components(GB 18469—2012).